Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report

Pembrolizumab has become the standard first‐line treatment for non‐small cell lung cancer (NSCLC) patients with high PD‐L1expression. MET exon 14 skipping is a rare mutation typically found in older, female, and non‐smoking patients with NSCLC. Herein, we report the case of a 71‐year‐old non‐smoking...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Thorac Cancer
Egile Nagusiak: Baba, Keisuke, Tanaka, Hisashi, Sakamoto, Hiroaki, Shiratori, Toshihiro, Tsuchiya, Junichiro, Ishioka, Yoshiko, Itoga, Masamichi, Taima, Kageaki, Tasaka, Sadatomo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons Australia, Ltd 2019
Gaiak:
Case Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360217/
https://ncbi.nlm.nih.gov/pubmed/30600919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12939
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak